Alzamend Neuro Announces Reverse Stock Split

Rhea-AI Summary

Alzamend Neuro (NASDAQ: ALZN) has announced a 1-for-9 reverse stock split effective May 12, 2025. The clinical-stage biopharmaceutical company, focused on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, implemented this measure primarily to maintain Nasdaq listing compliance with the minimum bid requirement of $1.00 per share.

The company's outstanding shares will decrease from approximately 7,208,591 to 800,954 shares. The stock will continue trading under the symbol "ALZN" with a new CUSIP number 02262M605. While the split affects all issued and outstanding shares, including equity incentive plans and outstanding options/warrants, it won't alter stockholders' percentage ownership. Stockholders entitled to fractional shares will receive cash payments instead.

Positive

• Helps maintain Nasdaq listing compliance by potentially increasing share price above $1.00
• Maintains stockholders' percentage ownership in the company
• Could improve stock marketability and appeal to certain institutional investors

Negative

• Indicates company's struggle to maintain minimum share price requirements
• Cash payments for fractional shares may force some small shareholders to liquidate partially
• Does not address underlying business fundamentals or market valuation concerns

Insights

Financial Analyst

Alzamend's 1-for-9 reverse split aims to maintain Nasdaq listing compliance but doesn't change fundamental company value.

Alzamend Neuro's announced 1-for-9 reverse stock split represents a technical adjustment designed primarily to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. This corporate action will mechanically reduce their outstanding shares from approximately 7.2 million to 800,954 while proportionately increasing the share price by a factor of nine.

For shareholders, this means each nine shares currently owned will convert to one share post-split on May 12, 2025. Those holding fewer than nine shares or left with fractional shares will receive cash payments instead. The company's market capitalization remains unchanged by this action, as does each investor's percentage ownership (except those cashed out due to fractional shares).

Maintaining Nasdaq listing is particularly important for clinical-stage biopharmaceutical companies like Alzamend, which is developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The continued listing provides better access to capital markets, increased share liquidity, and greater visibility - all crucial for financing ongoing research and development.

The reverse split affects all issued and outstanding common shares and adjusts the number of shares available under equity incentive plans. It also reduces the number of shares issuable upon exercise of outstanding stock options or warrants proportionately. The par value remains unchanged at $0.0001 per share.

While reverse splits often carry negative market perception, they represent administrative adjustments rather than fundamental business changes. The action does not alter Alzamend's clinical programs, intellectual property, or operational strategy.

ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that Alzamend’s board of directors approved a one-for-nine reverse stock split of Alzamend’s common stock (“Common Stock”) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company’s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol “ALZN”. The new CUSIP number for the Common Stock will be 02262M605. The reverse stock split is part of the Company’s plan to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

The reverse stock split affects all issued and outstanding shares of the Company’s Common Stock, as well as the number of shares of Common Stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split reduces the number of shares of Common Stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the reverse split. The par value of the Company’s Common Stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment. As of the date of this press release, Alzamend has 7,208,591 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 800,954 shares of Common Stock after the reverse stock split is effective.

Computershare Trust Company, N.A. (“Computershare”), is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders for receiving payment for any fractional shares.

About Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.

Contacts:
Email: Info@Alzamend.com or call: 1-844-722-6333

FAQ

What is the ratio of Alzamend Neuro's (ALZN) reverse stock split announced in May 2025?

Alzamend Neuro announced a 1-for-9 reverse stock split, effective May 12, 2025.

Why did Alzamend Neuro (ALZN) implement a reverse stock split in 2025?

The reverse stock split was implemented to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.

How many shares will ALZN have outstanding after the May 2025 reverse split?

After the reverse stock split, ALZN's outstanding shares will decrease from 7,208,591 to approximately 800,954 shares.

What happens to ALZN shareholders who own fractional shares after the reverse split?

Shareholders entitled to fractional shares will receive cash payments instead of partial shares.

Will the reverse stock split affect ALZN shareholders' ownership percentage?

No, the reverse stock split will not alter any stockholder's percentage interest in the company, except for minor adjustments due to fractional shares.